Journal Mobile Options
Table of Contents
Vol. 219, No. 5, 2005
Issue release date: September–October 2005
Ophthalmologica 2005;219:309–315

Attenuation and Delay of Diabetic Cataracts by Antioxidants: Effectiveness of Pyruvate after Onset of Cataract

Varma S.D. · Hegde K.R. · Kovtun S.
Department of Ophthalmology and Visual Sciences, School of Medicine, University of Maryland, Baltimore, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Cataract is one of the most significant vision-impairing complications of diabetes. The present study examined the feasibility of inhibiting cataract formation by treatment with pyruvate, a metabolite known to effectively scavenge reactive species of oxygen and inhibit protein glycation, both known to be involved in the genesis of diabetic cataracts. In addition, pyruvate stimulates tissue metabolism, which is depressed with the onset of cataract formation. The objective of our experiments was to determine if this compound could be effective in offsetting the progress of cataract, specifically if administered after the diabetes-induced lens changes have begun, as opposed to the previous reports wherein it has been reported to delay cataract formation if administered prophylactically with the immediate onset of diabetes. Diabetes was induced by intraperitoneal administration of streptozotocin to mice. Lens transparency was assessed by slit lamp examination and its photography. ATP was determined enzymatically by reacting it with luciferin-luciferase mixture and measuring the fluorescence intensity. The findings described herein are in accordance with this possibility. The incidence of cataract in the group of diabetic animals, where treatment with pyruvate was initiated after the initial lens changes set in, was significantly lower at all times of observation in comparison to the untreated diabetic group. In addition, the severity of opacities in the pyruvate-treated group, when present, was much minor, the transparency of these cases being close to that in the control animals. The ophthalmic findings are supported biochemically by ATP levels, which were significantly higher in the pyruvate group in comparison to the untreated group. The present findings emphasize the clinical usefulness of initiating treatment with anti-oxidants and metabolic agonists even when the lens changes are detected at the time of the diabetes diagnosis. The latter usually comes much later than the onset of visual aberrations. Prophylaxis is not an absolute requirement.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Chylack LT Jr, Kinoshita JH: A biochemical evaluation of a cataract induced in a high-glucose medium. Invest Ophthalmol 1969;8:401–412.
  2. Varma SD, Mikuni I, Kinoshita JH: Flavonoids as inhibitors of lens aldose reductase. Science 1975;188:1215–1216.
  3. Varma SD, Kinoshita JH: Inhibition of aldose reductase of flavonoids. Their possible role in the prevention of diabetic cataracts. Biochem Pharmacol 1976;25:2505–2513.
  4. Varma SD, Mizuno A, Kinoshita JH: Diabetic cataracts and flavonoids. Science 1977;195:205–206.
  5. Kador PF, Akagi Y, Kinoshita JH: The effect of aldose reductase and its inhibition on sugar cataract formation. Metabolism 1986;35(4 suppl 1):15–19.
  6. Varma SD, Schocket SS, Richards RD: Implications of aldose reductase in cataracts in human diabetes. Invest Ophthalmol Vis Sci 1979;18:237–241.
  7. Lerner BC, Varma SD, Richards RD: Polyol pathway metabolites in human cataracts. Correlation of circulating glycosylated hemoglobin content and fasting blood glucose levels. Arch Ophthalmol 1984;102:917–920.
  8. Varma SD, Kumar S, Richards RD: Light-induced damage to ocular lens cation pump. Prevention by vitamin C. Proc Natl Acad Sci USA 1979;76:3504–3506.
  9. Spector A: The search for a solution to senile cataracts. Proctor Lecture. Invest Ophthalmol Vis Sci 1984;25:130–146.
  10. Zigler JS, Goosey JD: Singlet oxygen as a possible factor in human senile nuclear cataract development. Curr Eye Res 1984;3:59–65.
  11. Srivastava SK, Lal AK, Ansari NH: Defense system of lens against oxidative damage: Effect of oxidative challenge on cataract formation in glutathione peroxidase deficient-acatalasemic mice. Exp Eye Res 1980;31:425–433.
  12. Spector A, Li S, Sigelman J: Age-dependent changes in the molecular size of human lens proteins and their relationship to light scatter. Invest Ophthalmol Vis Sci 1974;13:795–798.
  13. Giblin FJ, Padgaonkar VA, Leveren VR, Lin LR, Lou MF, Dickerson JE Jr, Dang L, Reddy VN: Nuclear light-scattering disulfide formation and membrane damage in lenses of older Guinea pigs treated with HBO. Exp Eye Res 1995;60:219–235.
  14. Lou MF, Dickerson JE Jr: Protein-thiol mixed disulfides in human lens. Exp Eye Res 1992;55:889–896.
  15. Pande J, Hanlon E, Pande A: A comparison of the environment of thiol groups in bovine and human gamma crystallins using raman spectroscopy. Exp Eye Res 2002;75:359–363.
  16. Varma SD, Chand D, Sharma YR, Kuck JF, Richards RD: Oxidative stress on lens and cataract formation: role of light and oxygen. Curr Eye Res 1984;3:35–57.
  17. Zhao W, Devamanoharan PS, Varma SD: Fructose-induced deactivation of G6PDH and its prevention by pyruvate: implications in cataract prevention. Free Rad Res 1998;29:315–320.
  18. Blakytny R, Harding JJ: Glycation (non-enzymatic glycosylation) inactivates glutathione reductase. Biochem J 1992;288:303–307.
  19. Monnier VM, Stevens VJ, Cerami A: Nonenzymatic glycosylation, sulfhydryl oxidation, and aggregation of lens proteins in experimental sugar cataracts. J Exp Med 1979;150:1098–1107.
  20. Swamy MS, Abraham EC: Lens protein composition, glycation and high-molecular-weight protein aggregation in aging rats. Invest Ophthalmol Vis Sci 1987;28:1693–1701.
  21. Perry RE, Swamy MS, Abraham EC: Progressive changes in lens crystallin glycation and high-molecular-weight aggregate formation leading to cataract development in streptozotocin-diabetic rats. Exp Eye Res 1987; 52:205–212.
  22. Nagaraj RH, Monnier VM: Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins. Biochim Biophys Acta 1995;1253:75–84.
  23. Stevens VJ, Rouzer CA, Monnier VM, Cerami A: Diabetic cataract formation and potential role of glycosylation of lens proteins. Proc Natl Acad Sci USA 1978;75:2918–2922.
  24. Hegde KR, Henein MG, Varma SD: Establishment of the mouse as a model animal for the study of diabetic cataracts. Ophthalmol Res 2003;35:12–18.
  25. Hegde KR, Henein MG, Varma SD: Establishment of mouse as an animal model for study of diabetic cataracts: biochemical studies. Diabetes Obes Metab 2003;5:113–119.
  26. Hegde KR, Varma SD: Morphogenetic and apoptotic changes in diabetic cataract. Prevention by pyruvate. Mol Cell Biochem 2004;262:233–237.
  27. Hegde KR, Varma SD: Prevention of cataract by pyruvate in experimentally diabetic mice. Mol Cell Biochem 2005;269:115–120.
  28. Fenton HJH, Jones HO: The oxidation of organic acid in presence of ferrous iron. Part 1. J Chem Soc Trans 1900;77:69–76.
  29. Holleman MAF: Note on the action of oxygenated water on alpha-keto acids and 1,2, dicetones. Recl Trav Chi Pays-bas Be 1904; 23:169–172.
  30. Sevag MG, Maiweg L: Respiration mechanisms of pneumococcus. J Exp Med 1934;60:95–105.
  31. Varma SD, Hegde K, Henein M: Oxidative damage to mouse lens in culture. Protective effect of pyruvate. Biochim Biophys Acta 2003;1621:246–252.
  32. Like AA, Appel MC, Williams, RM, Rossini A: Streptozotocin-induced pancreatic insulitis in mice. Morphologic and physiologic studies. Lab Invest 1978;38:470–486.
  33. Leiter EH, Gerling IC, Flynn JC: Spontaneous insulin-dependent diabetes mellitus in nonobese diabetic mice: comparisons with experimentally induced IDDM; in McNeill JH (ed): Experimental Models of Diabetes. Boca Raton, CRCLL Press, 1999, pp 257–295.
  34. Brunwald E, Fauci A, Kasper S, Longo DL, Jameson JL, Hanser SL: Harrison’s Principles of Internal Medicine, ed 15. New York, McGraw-Hill, 2001, vol 2, p 2111.
  35. Wolff SP, Dean RT: Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem J 1987;245:243–250.
  36. West ES, Todd WR, Mason HS, Van Bruggen JT: Text Book of Biochemistry. London, MacMillan, 1970, chap 24, p 1115.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50